Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Sponsor
Chinese Academy of Medical Sciences
Study ID
NCT03535961
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The hypothesis of this study is to discover if the all-oral therapy with apatinib plus oral Etoposide can shrink or slow the growth of pretreated HER2 negative metastatic breast cancer.

Key Dates

Start date
May 1, 2017
Status verified
Dec 2020
Primary completion
May 1, 2019
Completion
May 1, 2019

Study Design

Enrollment
32 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: apatinib+oral etoposide
    apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle

Primary Outcome Measure

objective response rate(ORR) [ Time Frame: up to 1 year after the last patient enrolled ]

Related Studies